Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. This work represents a key milestone in the company’s chemistry, manufacturing and controls (CMC) strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation.
The program will focus on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates required for downstream manufacturing and formulation. The effort will be conducted in collaboration with Dalton Pharma Services and is intended to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness and future clinical supply requirements.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology that targets solid tumours. For more information, visit https://oncoinnovations.com/.
This development is significant because it moves ONC010 closer to clinical trials, potentially offering a new treatment option for patients with solid tumours. The scalability of the manufacturing process is critical for ensuring that the drug can be produced in sufficient quantities for future studies and, if successful, for commercial use.
For the full press release, visit https://nnw.fm/kfFWv.
